(19)
(11) EP 1 794 143 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.12.2008 Bulletin 2008/52

(45) Mention of the grant of the patent:
09.07.2008 Bulletin 2008/28

(21) Application number: 05786700.4

(22) Date of filing: 22.08.2005
(51) International Patent Classification (IPC): 
C07D 333/58(2006.01)
C07D 209/14(2006.01)
A61K 31/343(2006.01)
A61P 25/08(2006.01)
 C07D 307/81(2006.01)
A61K 31/381(2006.01)
A61K 31/404(2006.01)
(86) International application number:
PCT/US2005/029814
(87) International publication number:
WO 2006/023861 (02.03.2006 Gazette 2006/09)

(54)

NOVEL BENZO-FUSED HETEROARYL SULFAMIDE DERIVATIVES USEFUL AS ANTICONVULSANT AGENTS

ALS ANTIKONVULSIVE MITTEL GEEIGNETE NEUE BENZOKONDENSIERTE HETEROARYLSULFAMIDDERIVATE

NOUVEAUX COMPOSÉS POLYAROMATIQUES DE TYPE HÉTÉROARYLSULFAMIDE POUVANT ÊTRE EMPLOYÉS EN TANT QU'AGENTS ANTICONVULSIVANTS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK YU

(30) Priority: 24.08.2004 US 604134 P

(43) Date of publication of application:
13.06.2007 Bulletin 2007/24

(73) Proprietor: Janssen Pharmaceutica NV
2340 Beerse (BE)

(72) Inventors:
  • PARKER, Michael H.
    Chalfot, PA 18914 (US)
  • REITZ, Allen B.
    Lansdale, PA 19446 (US)
  • MARYANOFF, Bruce E.
    Forest Grove, PA 18922 (US)

(74) Representative: Kirsch, Susan Edith et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA
London WC1A 2RA (GB)


(56) References cited: : 
EP-A- 0 483 881
WO-A-02/096424
 WO-A-97/19682
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).